BioVie Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
/ 
Frequently asked questions
To buy BioVie Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for BioVie Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for BioVie Inc. is BIVI:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
BioVie Inc. has its primary listing on NASDAQ (Small cap). You can trade BioVie Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, BioVie Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include BioVie Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like BioVie Inc..